Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23621142 | 0.95 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL23620924 | 0.85 | TLR7 (0.44) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL15689328 | 0.81 | ADORA2A (0.65) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL29394367 | 0.81 | ADORA2A (0.65) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL17935695 | 0.81 | ADORA3 (0.52) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL17935694 | 0.75 | ADORA3 (0.54) | ADORA2AADORA1ADORA2BADORA3ABL1 | |
| SCHEMBL23621012 | 0.75 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL4903374 | 0.75 | ABL1 (0.38) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL4298068 | 0.74 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL17935693 | 0.68 | ADORA3 (0.47) | ADORA2AADORA1ADORA2BADORA3FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322782-A1 | SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-12 | — | — | US | disclosed |
| US-20230322782-A1 | SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-12 | — | — | US | disclosed |
| US-11680067-B2 | Small molecules for the treatment of primary cancer and cancer metastasis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680067-B2 | Small molecules for the treatment of primary cancer and cancer metastasis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210206769-A1 | Small Molecules for the Treatment of Primary Cancer and Cancer Metastasis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680067-B2 | Small molecules for the treatment of primary cancer and cancer metastasis | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20230322782-A1 | SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | EPCAM, MKI67, KRAS | ADORA2A 3164/4885ADORA1 3923/4885ADORA2B 3679/4885 |
| US-20210206769-A1 | Small Molecules for the Treatment of Primary Cancer and Cancer Metastasis | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.